Neha Berry1, Saroj Kant Sinha2, Anish Bhattacharya3, K K Prasad1, Chetana Vaishnavi1, Kim Vaiphei4, Jayanta Samanta1, Raghavendra Prasada1, Narendra Dhaka1, Rakesh Kochhar1. 1. Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh, 160012, India. 2. Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh, 160012, India. sarojksinha@hotmail.com. 3. Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India. 4. Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Abstract
BACKGROUND: Disease activity in ulcerative colitis (UC) is best assessed clinically by Mayo score. 18-Fluorodeoxyglucose positron emission tomography-computerized tomography (FDG PET-CT) is a noninvasive imaging technique to assess extent, disease activity and response to treatment of UC, especially in high risk population or patients unwilling for endoscopy. AIMS: We conducted a prospective observational study with the aim of assessing and correlating UC disease activity by clinical criteria, endoscopy, histology, serum and fecal biomarkers, and FDG PET-CT. METHODS: Sixty eligible patients of UC were enrolled into three groups (26 remission, 24 moderate and 10 severe activity) as per Mayo score and FDG PET-CT was performed within 72 h of colonoscopy. ESR, CRP, and fecal calprotectin (FC) levels were determined for all patients. RESULTS: Of 60 enrolled patients, 10% patients had proctitis, 43.3% left-sided colitis, and 46.7% extensive colitis. ESR, CRP, FC levels, and rectal PET activity were significantly higher in groups with moderate and severe disease activity. Rectal PET activity showed a significant correlation with the Mayo score (k = 0.465, p < 0.001), endoscopic subscore (k = 0.526, p < 0.001), histological score (k = 0.496, p < 0.001), and FC (k = 0.279, p = 0.031). Extent evaluation by FDG PET-CT and colonoscopy showed a significant correlation (k = 0.582, p < 0.001). Besides, FDG PET-CT identified sacroiliitis in one patient and adenocarcinoma in one patient. CONCLUSION: FDG PET-CT is a reliable noninvasive tool for detection of disease activity, extent in UC with good correlation with Mayo score, histology and fecal biomarkers and accurate predictor of disease remission.
BACKGROUND: Disease activity in ulcerative colitis (UC) is best assessed clinically by Mayo score. 18-Fluorodeoxyglucose positron emission tomography-computerized tomography (FDG PET-CT) is a noninvasive imaging technique to assess extent, disease activity and response to treatment of UC, especially in high risk population or patients unwilling for endoscopy. AIMS: We conducted a prospective observational study with the aim of assessing and correlating UC disease activity by clinical criteria, endoscopy, histology, serum and fecal biomarkers, and FDG PET-CT. METHODS: Sixty eligible patients of UC were enrolled into three groups (26 remission, 24 moderate and 10 severe activity) as per Mayo score and FDG PET-CT was performed within 72 h of colonoscopy. ESR, CRP, and fecal calprotectin (FC) levels were determined for all patients. RESULTS: Of 60 enrolled patients, 10% patients had proctitis, 43.3% left-sided colitis, and 46.7% extensive colitis. ESR, CRP, FC levels, and rectal PET activity were significantly higher in groups with moderate and severe disease activity. Rectal PET activity showed a significant correlation with the Mayo score (k = 0.465, p < 0.001), endoscopic subscore (k = 0.526, p < 0.001), histological score (k = 0.496, p < 0.001), and FC (k = 0.279, p = 0.031). Extent evaluation by FDG PET-CT and colonoscopy showed a significant correlation (k = 0.582, p < 0.001). Besides, FDG PET-CT identified sacroiliitis in one patient and adenocarcinoma in one patient. CONCLUSION: FDG PET-CT is a reliable noninvasive tool for detection of disease activity, extent in UC with good correlation with Mayo score, histology and fecal biomarkers and accurate predictor of disease remission.
Authors: Anis Ahmadi; Qin Li; Keith Muller; Dennis Collins; John F Valentine; Walter Drane; Steven Polyak Journal: Inflamm Bowel Dis Date: 2010-06 Impact factor: 5.325
Authors: Alexander C von Roon; Leonidas Karamountzos; Sanjay Purkayastha; George E Reese; Ara W Darzi; Julian P Teare; Paraskevas Paraskeva; Paris P Tekkis Journal: Am J Gastroenterol Date: 2007-02-23 Impact factor: 10.864
Authors: Taina Sipponen; Johanna Haapamäki; Erkki Savilahti; Henrik Alfthan; Esa Hämäläinen; Henna Rautiainen; Jari Koskenpato; Hannu Nuutinen; Martti Färkkilä Journal: Scand J Gastroenterol Date: 2012-04-23 Impact factor: 2.423
Authors: David T Rubin; Bonnie L Surma; Samuel J Gavzy; Kerry M Schnell; Alana P Bunnag; Dezheng Huo; Daniel E Appelbaum Journal: Inflamm Bowel Dis Date: 2009-05 Impact factor: 5.325
Authors: James D Lewis; Shaokun Chuai; Lisa Nessel; Gary R Lichtenstein; Faten N Aberra; Jonas H Ellenberg Journal: Inflamm Bowel Dis Date: 2008-12 Impact factor: 5.325
Authors: Yan Li; Michael Khamou; Benedikt Michael Schaarschmidt; Lale Umutlu; Michael Forsting; Aydin Demircioglu; Johannes Haubold; Anna Katharina Koch; Nils-Martin Bruckmann; Lino Morris Sawicki; Ken Herrmann; James Hunter Boone; Jost Langhorst Journal: Br J Radiol Date: 2020-06-24 Impact factor: 3.039